RameshKRamanathanMD

Oncology • Scottsdale, AZ

Physician

Join to view full profile

Dr. Ramanathan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Ramanathan's full profile

Already have an account?

Office
13400 E Shea Blvd
Scottsdale, AZ 85259
Phone+1 480-301-8000

Fax+1 480-301-8367
Is this information wrong?

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 1993 - 1995
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1988 - 1991
Karnataka Institute of Medical ScienceClass of 1986

Certifications & Licensure

AZ State Medical License 2007 - 2026
FL State Medical License 1999 - 2025
CA State Medical License 1993 - 2025
IN State Medical License 2003 - 2017
WI State Medical License 1987 - 2017
IL State Medical License 1989 - 2014
PA State Medical License 1991 - 2012
NY State Medical License 1991 - 1992
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

Clinical Trials

Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer Start of enrollment: 1998 Nov 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 1998 Oct 01
Completed
Phase 3
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2 Start of enrollment: 1999 Sep 01
Completed
Phase 2
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Start of enrollment: 1996 Jan 01
Completed
Phase 1
Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer Start of enrollment: 1998 May 01
Completed
Phase 1
Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 Jun 01
Completed
Phase 1
Safety Study of S-CKD602 in Patients With Advanced Malignancies Start of enrollment: 2003 Sep 01
Completed
Phase 1
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors Start of enrollment: 2008 Jan 01
Terminated
Phase 1
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors Start of enrollment: 2010 Jul 01
Completed
Phase 1
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Start of enrollment: 2011 Jan 03
Completed
Phase 1
Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer Start of enrollment: 2011 May 01
Completed
Phase 2
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Jan 01
Completed
Phase 1
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer Start of enrollment: 2011 Nov 01
Completed
Phase 1, Phase 2
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA Start of enrollment: 2013 May 01
Completed
Phase 1, Phase 2
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma Start of enrollment: 2013 Nov 01
Terminated
Phase 1
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients Start of enrollment: 2016 Jul 06
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.
Michael S. Gordon, John Nemunaitis, Minal A. Barve, Zev A. Wainberg, Erika Hamilton, Ramesh K. Ramanathan, George W. Sledge, Huibin Yue, Susan E. Morgan-Lappe, Martha ...> ;Molecular Cancer Therapeutics. 2021 Jul 26
9 citations
Postbariatric hypoglycemia: symptom patterns and associated risk factors in the Longitudinal Assessment of Bariatric Surgery study
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Surgery for Obesity and Related Diseases. 2021 May 19
8 citations
SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.
Naomi Fei, Sijin Wen, Rajesh Ramanathan, Melissa E. Hogg, Amer H. Zureikat, Michael T. Lotze, Nathan Bahary, Aatur D. Singhi, Herbert J. Zeh, Brian A. Boone> ;Clinical and Translational Science. 2021 May 18
1 citations
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors.
Koji Ando, Al Ozonoff, Shin Yin Lee, Michael Voisine, Julian Taylor Parker, Ryota Nakanishi, Sho Nishimura, Jing Yang, Zhao Grace, Ben Tran, Thomas J. Diefenbach, Yosh...> ;Clinical Colorectal Cancer. 2021 Jun 1
26 citations
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.
Devalingam Mahalingam, Manish R. Patel, Jasgit C. Sachdev, Lowell L. Hart, Niels Halama, Ramesh K. Ramanathan, John Sarantopoulos, Dirk Völkel, Ashraf Youssef, Floris ...> ;British Journal of Clinical Pharmacology. 2020 Sep 1
9 citations
Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer.
David Goldstein, Daniel D. Von Hoff, E. Gabriela Chiorean, Michele Reni, Josep Tabernero, Ramesh K. Ramanathan, Marc F. Botteman, Abdalla Aly, Sandra Margunato-Debay, ...> ;Pancreas. 2020 Jul 1
17 citations
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
Ramesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, George Blumenschein Jr, Donald Richards, Isabelle Genvresse, Susanne Reschke, Camille Granvil, Adam Skubala, Caro...> ;Targeted Oncology. 2020 Apr 1
14 citations
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.
John H. Strickler, Patricia LoRusso, Ravi Salgia, Yoon-Koo Kang, Chia Jui Yen, Chia-Chi Lin, Peter Ansell, Monica Motwani, Shekman Wong, Huibin Yue, Lan Wang, Edward B...> ;Molecular Cancer Therapeutics. 2020 May 1
97 citations
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.
Ana De Jesus-Acosta, Elizabeth A. Sugar, Peter J. O'Dwyer, Ramesh K. Ramanathan, Daniel D. Von Hoff, Zeshaan A. Rasheed, Lei Zheng, Asma Begum, Robert A. Anders, Anirb...> ;British Journal of Cancer. 2020 Feb 18
52 citations
Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical ...
Gayle S. Jameson, Erkut Borazanci, Hani M. Babiker, Elizabeth Poplin, Anna A. Niewiarowska, Michael S. Gordon, Michael T. Barrett, Adam Rosenthal, Amy Stoll-D'Astice, ...> ;JAMA Oncology. 2020 Jan 1
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncolo...
Ramesh K. Ramanathan, Daniel D. Von Hoff, Ferry A.L.M. Eskens, George R. Blumenschein, Donald A. Richards, Isabelle Genvresse, Susanne Reschke, Camille Granvil, Adam S...> ;Targeted Oncology. 2020 Dec 1
2 citations
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Vera Gorbunova, J. Thaddeus Beck, Ralf Hofheinz, P. García-Alfonso, Marina Nechaeva, Antonio Cubillo Gracian, László Mangel, Elena Elez Fernandez, Dustin A. Deming, Ra...> ;British Journal of Cancer. 2019 Aug 1
280 citations
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial
Rachna T. Shroff, Milind Javle, Lianchun Xiao, Ahmed Kaseb, Gauri R. Varadhachary, Robert A. Wolff, Kanwal Pratap Singh Raghav, Michiko Iwasaki, Peter Masci, Ramesh K....> ;JAMA Oncology. 2019 Jun 1
214 citations
Hepatocytes direct the formation of a pro-metastatic niche in the liver
Jae W. Lee, Meredith L. Stone, Paige M. Porrett, Stacy K. Thomas, Chad A. Komar, Joey H. Li, Devora Delman, Kathleen Graham, Whitney L. Gladney, Xia Hua, Taylor A. Bla...> ;Nature. 2019 Mar 6
177 citations
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma...
Ramesh K. Ramanathan, Shannon McDonough, Philip A. Philip, Sunil R. Hingorani, Jill Lacy, Jeremy S. Kortmansky, Jaykumar Ranchodbhai Thumar, E. Gabriela Chiorean, Anth...> ;Journal of Clinical Oncology. 2019 Feb 28
11 citations
A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer.
Ramesh K. Ramanathan, Gary W. Thomas, Alok A. Khorana, Satish Shah, Cathy Zhou, Sofia Wong, George Cole, Danelle F. James, Nashat Y. Gabrail> ;Oncology. 2019 Jan 1
34 citations
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
Vera Gorbunova, J. Thaddeus Beck, Ralf Hofheinz, P. García-Alfonso, Marina Nechaeva, Antonio Cubillo Gracian, László Mangel, Elena Elez Fernandez, Dustin A. Deming, Ra...> ;British Journal of Cancer. 2019 Jan 22
67 citations
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
John H. Strickler, Colin D. Weekes, John Nemunaitis, Ramesh K. Ramanathan, Rebecca S. Heist, Daniel Morgensztern, Eric Angevin, Todd M. Bauer, Huibin Yue, Monica Motwa...> ;Journal of Clinical Oncology. 2018 Oct 4
6 citations
Novel immunotherapy strategies for hepatobiliary cancers
Thomas DeLeon, Yumei Zhou, Bolni Marius Nagalo, Raquel T. Yokoda, Daniel H. Ahn, Ramesh K. Ramanathan, Marcela Salomao, Bashar Aqel, Amit Mahipal, Tanios Bekaii-Saab, ...> ;Immunotherapy. 2018 Sep 1
17 citations
Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma.
Daniel H. Ahn, Ramesh K. Ramanathan, Tanios Bekaii-Saab> ;Cancers. 2018 Jun 11
172 citations
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
, , , , , , , , , , , , , , , > ;Journal of Clinical Oncology. 2018 May 23
25 citations
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.
Jordan Berlin, Ramesh K. Ramanathan, John H. Strickler, Deepa S. Subramaniam, John L. Marshall, Yoon-Koo Kang, Robert Hetman, Matthew W. Dudley, Jiewei Zeng, Caroline ...> ;British Journal of Cancer. 2018 Mar 12
90 citations
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Stergios J. Moschos, Ryan J. Sullivan, Wen-Jen Hwu, Ramesh K. Ramanathan, Alex A. Adjei, Peter C.C. Fong, Ronnie Shapira-Frommer, Hussein Tawbi, Joseph Rubino, Thomas ...> ;JCI Insight. 2018 Feb 22
18 citations
Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma
Thomas DeLeon, Daniel H. Ahn, James M Bogenberger, Panos Z. Anastasiadis, Mansi Arora, Ramesh K. Ramanathan, Bashar Aqel, George Vasmatzis, Mark J. Truty, Rahmi Oklu, ...> ;Future Oncology. 2018 Feb 20
25 citations
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors
Glen J. Weiss, Gayle S. Jameson, Daniel D. Von Hoff, Barbara Valsasina, Cristina Davite, Claudia Di Giulio, Francesco Fiorentini, Rachele Alzani, Patrizia Carpinelli, ...> ;Investigational New Drugs. 2018 Feb 1
Join now to see all

Journal Articles

Targeting the Stroma in Pancreatic Cancer
Daniel H Ahn, Ramesh K Ramanathan, Annals of Palliative Medicine

Press Mentions

Biological Breakthroughs in Pancreas CancerOctober 10th, 2017
Expert Hopes Novel Approaches Improve Outlook in Pancreatic CancerMarch 7th, 2017
Shop TalkOctober 10th, 2014

Grant Support

Rndm Ph2 NON Compare Of SB-715992 Wkly Or Evry 3 WKS In Metastatic Col CancerNational Center For Research Resources2005
Ph1 Pharmco Stdy ST1571 PTS W/Adv Malig Levels Liver DysfunctionNational Center For Research Resources2005
Ph1 Pharmaco Epothilone B Analogue BMS-247550 Adv Malign LiverNational Center For Research Resources2005
Ph1 Pharm PS341 In PTS W/Adv Malign Varying Degrees Renal Dysf CtepNational Center For Research Resources2005
Ph1 (17-Dmag) In PTS W/Adv Solid TumorsNational Center For Research Resources2005
A Phase I Trial Of Weekly 17-Allyamino-17 Demethoxygeldanamycin (17AAG)National Center For Research Resources2005
A Ph1b Stdy MUCI Pulsed Dendritic Cell Vaccine In PTS W/Resected PancreaticNational Center For Research Resources2005
PHI Study Wkly Docetaxel In Combo W/CapecitabineNational Center For Research Resources2004
Ph2 Trial Rebeccamycin In Hepatobiliary CancerNational Center For Research Resources2004
Ph1 Pharmco Stdy ST1571 PTS W/Adv Malig. Liver DisorderNational Center For Research Resources2004
PH I Pharmacokinetics Stdy ST1571 In Advanced MalignancyNational Center For Research Resources2004
A Phase I Trial Of Weekly 17AAGNational Center For Research Resources2004
Herceptin, Gemcitabine For Metastatic Pancreatic CancerNational Center For Research Resources2000–2002
Gadolinium Texaphyrin Radiotherapy In Biliary/Pancreas CNational Center For Research Resources2000–2002
9 Nitro Camptothecin In Advanced Colorectal CancerNational Center For Research Resources2000–2002
Dose Escalation Trial Of 100aa Synthetic Mucin Peptide Pancreatic CancerNational Center For Research Resources1999–2002
Phase I Dose Escalation Trial Of Synthetic Mucin Peptide On Pancreatic CancerNational Center For Research Resources1999